54 related articles for article (PubMed ID: 35743122)
1. Factors correlating the expression of PD-L1.
Lu F; Wang E; Liu H
BMC Cancer; 2024 May; 24(1):642. PubMed ID: 38796458
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.
Ozawa N; Yokobori T; Osone K; Katayama C; Suga K; Komine C; Shibasaki Y; Shiraishi T; Okada T; Kato R; Ogawa H; Sano A; Sakai M; Sohda M; Ojima H; Miyazaki T; Motegi Y; Ide M; Yao T; Kuwano H; Shirabe K; Saeki H
Sci Rep; 2021 Jun; 11(1):13077. PubMed ID: 34158547
[TBL] [Abstract][Full Text] [Related]
3. γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies.
Shah K; Boghozian RA; Kartsonaki C; Shah KA; Vallis KA
Diagn Cytopathol; 2016 Feb; 44(2):141-6. PubMed ID: 26667983
[TBL] [Abstract][Full Text] [Related]
4. Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M; Espinoza M; Elliott A; Xiu J; Seeber A; El-Deiry W; Antonarakis ES; Graff SL; Hall MJ; Borghaei H; Hoon DSB; Liu SV; Ma PC; McKay RR; Wise-Draper T; Marshall J; Sledge GW; Spetzler D; Zhu H; Hsiehchen D
Nat Cancer; 2024 Mar; ():. PubMed ID: 38528112
[TBL] [Abstract][Full Text] [Related]
5. Effects of unburned tobacco smoke on inflammatory and oxidative mediators in the rat prefrontal cortex.
Vivarelli F; Morosini C; Rullo L; Losapio LM; Lacorte A; Sangiorgi S; Ghini S; Fagiolino I; Franchi P; Lucarini M; Candeletti S; Canistro D; Romualdi P; Paolini M
Front Pharmacol; 2024; 15():1328917. PubMed ID: 38333013
[TBL] [Abstract][Full Text] [Related]
6. A DNA Replication Stress-Based Prognostic Model for Lung Adenocarcinoma.
Shi S; Wen G; Lei C; Chang J; Yin X; Liu X; Huang S
Acta Naturae; 2023; 15(3):100-110. PubMed ID: 37908773
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
8. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
9. γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma.
Sakurai E; Ishizawa H; Kiriyama Y; Michiba A; Hoshikawa Y; Tsukamoto T
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743122
[TBL] [Abstract][Full Text] [Related]
10. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
14. The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.
Osoegawa A; Hiraishi H; Hashimoto T; Takumi Y; Abe M; Takeuchi H; Miyawaki M; Okamoto T; Sugio K
In Vivo; 2018; 32(1):171-177. PubMed ID: 29275316
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
